As a 501(c)(3) nonprofit, we depend almost entirely on donations from people like you.
We really need your help to continue this work! Please consider making a donation.
Subscribe here and join over 13,000 subscribers to our free weekly newsletter

Donations tie drug firms and nonprofits
Key Excerpts from Article on Website of Philadelphia Inquirer (Philadelphia's leading newspaper)

Philadelphia Inquirer (Philadelphia's leading newspaper), May 28, 2006
Posted: November 11th, 2006

The American Diabetes Association...privately enlisted an Eli Lilly & Co. executive to chart its growth strategy. The National Alliance on Mental Illness...lobbies for treatment programs that also benefit its drug-company donors. The National Gaucher Foundation...gets nearly all its revenue from one drugmaker, Genzyme Corp. Many patient groups and drug companies maintain close, multimillion-dollar relationships while disclosing limited or no details about the ties. An Inquirer examination of six groups, each a leading advocate for patients in a disease area, found that the groups rarely disclose such ties when commenting or lobbying about donors' drugs. Combined, the six received at least $29 million from drug companies last year. The amount ranged from 2 percent to 7 percent of revenue at the Arthritis Foundation, to 89 percent to 91 percent at the much smaller National Gaucher Foundation. The funding usually comes from the companies' marketing or sales divisions, not charity offices. Grants often rise with promotional spending as a drug hits the market and fall when sales ebb. Donations from Merck and Pfizer Inc. to the Arthritis Foundation more than doubled, to at least $1.65 million combined, in 2000 as they launched Vioxx and Celebrex. Merck explicitly wove the foundation into sales strategies. In 2000-2001, the American Diabetes Association did not disclose an unusual gift from Lilly: a lent executive, Emerson "Randy" Hall Jr., who moved into its Alexandria, Va., headquarters and coached it on growth strategies, all paid by Lilly.

Note: If you want to understand how the huge pharmaceutical industry influences what you know about their drugs, this article is a must read. You may first want to read a riveting two-page summary of an expos by the former editor-in-chief of the New England Journal of Medicine, who details major collusion and corruption in the pharmaceutical industry at

Latest News

Key News Articles from Years Past